Celgene successfully blocks institution of inter partes review on three patents listed in the Orange Book for its blockbuster REVLIMID® product
Client(s) Celgene Corporation
Jones Day represented Celgene Corporation in successfully blocking institution of inter partes review ("IPR") of three patents covering the use of Celgene's REVLIMID® brand drug to treat myelodysplastic syndrome (“MDS”). Following Celgene's filing of its Patent Owner Preliminary Response to each petition, the Patent Trial and Appeal Board ("PTAB") denied institution of inter partes review for all three patents, finding that Dr. Reddy’s Laboratories, Inc. had not shown a reasonable likelihood of prevailing in its unpatentability challenges.
Dr. Reddy's Laboratories, Inc. v. Celgene Corp., IPR Nos. 2018-01504, -01507, -01509 (PTAB)